Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Benefits and problems of allogeneic stem cell transplantation as multiple myeloma treatment

Prof Nicolaus Kröger - University Hospital Hamburg, Hamburg, Germany
Benefits and problems of allogeneic stem cell transplantation as multiple myeloma treatment ( Prof Nicolaus Kröger -  University Hospital Hamburg, Hamburg, Germany )
1 Nov 2016

Biomarkers of sensitivity and resistance

Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Biomarkers of sensitivity and resistance ( Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
26 Oct 2016

Editor's ESMO 2016 roundup

Prof Gordon McVie - Editor in Chief, ecancer
Editor's ESMO 2016 roundup ( Prof Gordon McVie - Editor in Chief, ecancer )
24 Oct 2016

CDK4/6 inhibitors for metastatic breast cancer

Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
CDK4/6 inhibitors for metastatic breast cancer ( Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
14 Oct 2016

ESMO 2016 conference highlights

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2016 conference highlights ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016

Lurbinectedin in PARP resistant breast cancer

Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in PARP resistant breast cancer ( Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016

Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate

Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate ( Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA )
10 Oct 2016

Highlights of ESMO 2016

Dr Andrés Cervantes - ESMO 2016 Scientific Chair
Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )
10 Oct 2016

Custirsen shows no survival benefit in metastatic prostate cancer

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Custirsen shows no survival benefit in metastatic prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
10 Oct 2016

Negative trial results of custirsen for metastatic prostate cancer

Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France
Negative trial results of custirsen for metastatic prostate cancer ( Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France )
10 Oct 2016

Advances for NSCLC in review

Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland
Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )
9 Oct 2016

Ceritinib following crizotinib relapse for ALK positive NSCLC

Dr Giorgio Scagliotti - University of Turin, Turin, Italy
Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016